Skip to content
akaturk Academic measurement
Search

Article detail · 2019 · article

Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation

ISSN0041-4301
YÖKSİS OpenAlex Open access · diamond TR Index
Year2019
Citations21OpenAlex
Citations17Semantic Scholar
Percentile%70.8
FWCI0.771.00 = world average
Scopus (SJR)Q3
WoS (JCR)Q4

Data source split

  • YÖKSİSYÖKSİS article record
  • YÖKSİS venueTURKISH JOURNAL OF PEDIATRICS
  • Catalog match (ISSN)Turkish Journal of Pediatrics
  • OpenAlexOpenAlex enrichment (abstract, citations, topics)
  • Semantic Scholarcitation count (not merged with OpenAlex)

Abstract

OpenAlex English

Atmaca M, Gülhan B, Atayar E, Karabay Bayazıt A, Candan C, Arıcı M, Topaloğlu R, Özaltın F. Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation. Turk J Pediatr 2019; 61: 657-663. ADCK4-related glomerulopathy is a recently recognized clinical entity associated with insidious onset in young children and a high potential to progress to chronic kidney disease in adolescents. Early initiation of exogenous coenzyme Q10 (CoQ10) supplementation in the asymptomatic period could be protective on renal functions. In the present study, we aimed to investigate long-term follow-up of patients that we have diagnosed during the asymptomatic period and in whom we started CoQ10 treatment. We analyzed long-term effects of CoQ10 on proteinuria and estimated glomerular filtration rate (eGFR) in this patient population. A total of 8 patients (4 female, 4 male) from 6 different families were included. The mean age at diagnosis and at last visit were 16.8±11.2 years and 20.7±11.7 years, respectively. None of the patients had extrarenal system involvement. At the time of initiation of treatment; median eGFR was 107.8 ml/min/1.73 m2, median proteinuria was 1008 mg/m2/day. After a median follow-up period of 25.3±5.8 months, median proteinuria decreased to 318.5 mg/m2/day (p=0.03) and median eGFR remained stable at 99.6 ml/min/1.73 m2 (p=0.21). Coenzyme Q10 treatment is effective for reducing proteinuria and seems to be renoprotective.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

21citationsOpenAlex · cited_by_count (cache / database)

8 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. 2022 Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiencyCitations 67 · OpenAlex
  2. 2022 Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiencyCitations 67 · OpenAlex
  3. 2022 Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiencyCitations 67 · OpenAlex
  4. 2022 Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathyCitations 48 · OpenAlex
  5. 2022 Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathyCitations 48 · OpenAlex
  6. 2022 Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathyCitations 48 · OpenAlex
  7. 2021 The Kidney in Mitochondrial DiseasesCitations 1 · OpenAlex
  8. 2022 The Kidney in Mitochondrial DiseasesCitations 0 · OpenAlex

Authors

8
  1. MUSTAFA ATMACA 1
  2. BORA GÜLHAN HACETTEPE ÜNİVERSİTESİ 2
  3. EMİNE ATAYAR 3
  4. AYSUN KARABAY BAYAZIT 4
  5. CENGİZ CANDAN 5
  6. MUSTAFA ARICI 6
  7. REZAN TOPALOĞLU 7
  8. FATİH ÖZALTIN HACETTEPE ÜNİVERSİTESİ 8